| Autor: |
Jaesh Naik, Ryan Dillon, Matthew Massello, Lewis Ralph, Zhuo Yang |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Journal of Comparative Effectiveness Research, Vol 12, Iss 3 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2042-6313 |
| DOI: |
10.2217/cer-2022-0113 |
| Popis: |
Aim: This study evaluates the cost–effectiveness of imipenem/cilastatin/relebactam (IMI/REL) for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in an ‘early adjustment prescribing scenario’. Methods: An economic model was constructed to compare two strategies: continuation of empiric piperacillin/tazobactam (PIP/TAZ) versus early adjustment to IMI/REL. A decision tree was used to depict the hospitalization period, and a Markov model used to capture longterm outcomes. Results: IMI/REL generated more quality-adjusted life years than PIP/TAZ, at an increased cost per patient. The incremental cost–effectiveness ratio of $17,529 per QALY is below the typical US willingness-to-pay threshold. Conclusion: IMI/RELmay represent a cost-effective treatment for payers and a valuable option for clinicians, when considered alongside patient risk factors, local epidemiology, and susceptibility data. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
